Koninklijke Philips N.V.

PHG • Medical - Devices

$25.89

— 0.00 (0.00%)

ResultadosÚltimo reporte: 31 mar 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$25.08B

Crecimiento

-0.2%

Flujo de caja

4/5

Tendencia

Mostly stable

Evidencia

Flujo de caja libre positivo · 0.93Flujo de caja libre consistente · 4/5Nivel de deuda manejable · 0.74Liquidez saludable · 1.32Tendencia de crecimiento negativa

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 6 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$25.89

Change0.00%

Shares Out968.53M

Market Cap$25.08B

52W Range21.95 - 33.44

Beta0.92

P/E37.13

P/S5.74

P/B1.97

P/FCF191.85

EV/Sales7.19

EV/EBITDA52.17

Price$25.89

Change0.00%

Shares Out968.53M

Market Cap$25.08B

52W Range21.95 - 33.44

Beta0.92

P/E37.13

P/S5.74

P/B1.97

P/FCF191.85

EV/Sales7.19

EV/EBITDA52.17

EV/FCF240.11

Earnings Yield2.69%

FCF Yield0.52%

Dividend Yield0.00%

Gross Margin45.18%

Oper. Margin7.98%

Profit Margin5.02%

Debt/Eq0.74

Current Ratio1.32

Quick Ratio0.94

Revenue 5Y-0.21%

Volume894.74K

Avg Volume1.07M

EPS Surprise0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

45/100

Fortaleza financiera

Deuda, caja, estabilidad

65/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

75/100

Por qué este puntaje▼

Flujo de caja libre positivo · 0.93Flujo de caja libre consistente · 4/5Nivel de deuda manejable · 0.74Liquidez saludable · 1.32Tendencia de crecimiento negativa

Analyst view

Analyst sentiment and price target

PHG

Analyst sentiment

Based on 22 analyst votes · 2026-09-05

68/100

Neutral

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 3/17/1980

Industria: Medical - Devices

P/B i: 1.97

Deuda / Patrimonio i: 0.74

Margen operativo: 7.98%

Margen neto: 5.02%

ROE i: -

ROIC: -

Salud financiera

Puntaje13 / 20

Deuda / Patrimonio: 0.74

Ratio corriente: 1.32

Ratio rápido: 0.94

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Koninklijke Philips N.V.

Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Fuente - Link

Competidores

BNTX DXCM LH MTD NTRA PODD SNN STE TEVA ZBH

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC

PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.

Zacks Investment Research

Philips advances women's health ultrasound with new single-transducer solution

September 3, 2026 FDA 510(k) cleared and CE marked, the eV14-2v combines exceptional image quality and broad clinical capabilities in one lightweight transducer, helping streamline exams, support diagnostic confidence, and improve the patient experience Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the eV14-2v transvaginal transducer, expanding its obstetrics and gynecology ultrasound portfolio. FDA 510(k) cleared and CE marked, the eV14-2v is designed to support a broad range of gynecology and early obstetrics exams by combining image quality and broad clinical capabilities in a single lightweight transducer.

GlobeNewsWire

Financial Analysis: Koninklijke Philips (NYSE:PHG) & Microbot Medical (NASDAQ:MBOT)

Koninklijke Philips (NYSE: PHG - Get Free Report) and Microbot Medical (NASDAQ: MBOT - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Insider and Institutional Ownership 13.7% of Koninklijke Philips

Defense World

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration

AMSTERDAM--(BUSINESS WIRE)-- #cardiology--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips' 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for ca.

Business Wire

Philips and Imricor launch cardiac interventional MR lab solution, expanding longstanding collaboration

August 27, 2026 The solution combines Philips' high-performance 1.5T MRI platform and advanced interventional workflow capabilities with Imrico r' s exclusive portfolio of systems and consumables for MR-guided cardiac interventions. Amsterdam, the Netherlands – August 27, 2026: Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-06	0.24	0.27	0.03
2026-02-10	0.565	0.7	0.135
2025-11-04	0.37	0.37	0
2025-07-29	0.3174	0.41	0.0926
2025-05-06	0.14	0.27	0.13
2025-02-19	0.55	0.54	-0.01
2024-10-28	0.35	0.35	0
2024-07-29	0.25	0.32	0.07
2024-04-29	0.26	0.28	0.02
2024-01-29	0.41	0.44	0.03
2023-10-23	0.18	0.36	0.18
2023-07-24	0.23	0.31	0.08